These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36815858)

  • 21. Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients.
    Selby PR; Heffernan AJ; Yeung D; Warner MS; Peake SL; Hahn U; Westley I; Shakib S; Roberts JA
    J Antimicrob Chemother; 2024 Mar; 79(3):567-577. PubMed ID: 38217845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children.
    Facchin A; Benyoub N; Elie V; Magreault S; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0159722. PubMed ID: 36880779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
    Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
    Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
    Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mutations in the
    Demin MV; Tikhomirov DS; Biderman BV; Drokov MY; Sudarikov AB; Tupoleva TA; Filatov FP
    Vopr Virusol; 2022 Mar; 67(1):37-47. PubMed ID: 35293187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation.
    Lim ZY; Cook G; Johnson PR; Parker A; Zuckerman M; Marks D; Wiltshire H; Mufti GJ; Pagliuca A
    Leuk Res; 2009 Feb; 33(2):244-9. PubMed ID: 18805583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients.
    Cojutti PG; Heffernan AJ; Tängdén T; Della Siega P; Tascini C; Roberts JA; Pea F
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0166522. PubMed ID: 36815856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.
    Zhao W; Baudouin V; Zhang D; Deschênes G; Le Guellec C; Jacqz-Aigrain E
    Clin Pharmacokinet; 2009; 48(5):321-8. PubMed ID: 19566115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
    Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
    Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
    Razonable RR; Paya CV
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.